Severe eosinophilic asthma: a roadmap to consensus

Roland Buhl(Johannes Gutenberg University Mainz), Stephen T. Holgate(University of Southampton), Santiago Quirce(Hospital Universitario La Paz), Liam G. Heaney(Queen's University Belfast), Pascal Chanez(Aix-Marseille Université), Ian Pavord(Oxford BioMedica (United Kingdom)), Marc Humbert(Inserm), Leif Bjermer(Lund University), J. Christian Virchow(Universitätsmedizin Rostock)
European Respiratory Journal
May 1, 2017
10.1183/13993003.00634-2017
Cited by 187

Related Papers

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k
Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
|Allergy|2004|1.1k
Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness
|Nature|2002|1.1k
Pathologic assessment of vasculopathies in pulmonary hypertension
|Journal of the American College of Cardiology|2004|713
Treatment strategies for allergy and asthma
|Nature reviews. Immunology|2008|687